drugset / Trial / NCT02421510

Efficacy, Safety, and Tolerability Study of Sotagliflozin as Adjunct Therapy in Adult Patients With Type 1 Diabetes Mellitus Who Have Inadequate Glycemic Control With Insulin Therapy

NCT02421510

Phase 3 Completed 782 enrolled Lexicon Pharmaceuticals Sanofi · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This Phase 3 study was intended to demonstrate superiority of either Sotagliflozin high dose or low dose versus placebo on glycosylated hemoglobin A1C (A1C) reduction at Week 24 when used as an adjunct in adult participants with type 1 diabetes mellitus (T1D) who have inadequate glycemic control with insulin therapy.

Timeline

Start
2015-05
Primary completion
2016-11
Completion
2017-06-23

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Sotagliflozin Small molecule 200 mg Oral
Subject Sotagliflozin Small molecule 400 mg Oral